biostudies-literatureUnknown28(22)Lim EAAstraZeneca<h4>Purpose</h4>To evaluate AZD4635, an adenosine A2A receptor antagonist, as monotherapy or in combination with durvalumab in patients with advanced solid tumors.<h4>Patients and methods</h4>In phase Ia (dose escalation), patients had relapsed/refractory solid tumors; in phase Ib (dose expansion), patients had checkpoint inhibitor-naïve metastatic castration-resistant prostate cancer (mCRPC) or colorectal carcinoma, non-small cell lung cancer with prior anti-PD-1/PD-L1 exposure, or other solid tumors (checkpoint-naïve or prior anti-PD-1/PD-L1 exposure). Patients received AZD4635 monotherapy (75-200 mg once daily or 125 mg twice daily) or in combination with durvalumab (AZD4635 75 or 100 mg once daily). The primary objective was safety; secondary objectives included antitumor activity and Clinical cancer research : an official journal of the American Association for Cancer Research4871-4884https://www.ebi.ac.uk/biostudies/studies/S-EPMC9660540biostudies-literaturePhase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.PMC9660540George DJMoorthy GSachsenmeier KFBauer TMUlahannan SLim EAChoe JHChen HKarlix JLKumar RDas MBendell JCPatel MRFalchook GSDrake CGPouliot GPRussell DLSidders BSHattersley MMPilling EAfalsePhase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.<h4>Purpose</h4>To evaluate AZD4635, an adenosine A2A receptor antagonist, as monotherapy or in combination with durvalumab in patients with advanced solid tumors.<h4>Patients and methods</h4>In phase Ia (dose escalation), patients had relapsed/refractory solid tumors; in phase Ib (dose expansion), patients had checkpoint inhibitor-naïve metastatic castration-resistant prostate cancer (mCRPC) or colorectal carcinoma, non-small cell lung cancer with prior anti-PD-1/PD-L1 exposure, or other solid tumors (checkpoint-naïve or prior anti-PD-1/PD-L1 exposure). Patients received AZD4635 monotherapy (75-200 mg once daily or 125 mg twice daily) or in combination with durvalumab (AZD4635 75 or 100 mg once daily). The primary objective was safety; secondary objectives included antitumor activity and 2022-01-01T00:00:00Z2022 Nov2026-05-28T06:13:15.615Z2025-04-04T14:18:40.42ZS-EPMC96605403604453110.1158/1078-0432.CCR-22-0612